The reported association between tardive dyskinesia and schizophrenic patients and D3 receptor gene variant is exciting, but should be interpreted cautiously given the complex nature of both schizophrenia and tardive dyskinesia.
Introduction
borne in mind before interpreting the results in a definitive fashion. The genetics of schizophrenia is a mystery wrapped within an enigma. This serious and arguably the most Genetics of schizophrenia expensive psychiatric disorder is also one of the most complex ones. There is considerable evidence indicatIt is quite apparent that schizophrenia is only partly ing the involvement of the dopamine system in the genetic in origin. Even among monozygotic twins, the pathophysiology of schizophrenia. For a century, there concordance for schizophrenia is less than 50%. It is has been a general agreement among scientists that also clear that this is a heterogeneous disease, with schizophrenia is a heterogeneous condition with differpossibly different neurobiological subtypes. Over the ent subtypes. There has, however, been no unanimity past decade, several different genetic markers have about the best way of subtyping schizophrenia. One been reported to be associated with schizophrenia, but way of subtyping this disorder is by assessing the have not been replicated consistently. The most effects of the most effective treatment for schizonotable example of this was the report of linkage to phrenia -the antipsychotic or neuroleptic drugs. chromosome 5q. 2 Though the initial evidence for linkIronically, it is a side-effect that may be useful for this age to schizophrenia was quite high, subsequently the purpose. 1 Tardive dyskinesia (TD) is a unique adverse finding could not be independently replicated. Furreaction to drugs in that it is the only known potenthermore, later studies in the same families using more tially persistent movement disorder caused by therainformative markers could not confirm the result. Folpeutically prescribed medications. TD occurs after lowing this disappointing experience, investigators long-term use of neuroleptics (which are typically became very cautious and few studies were reported dopamine receptor-blocking agents), and is much more as positive for several years. As more experience was common in the elderly than in younger adults. The developed and genome scans progressed, the prospect overall prevalence of TD among patients chronically of coming to the end of the genome without finding treated with neuroleptics is 20-30%, but varies accordany genes began to become a greater fear than that of ing to the specific sample studied. Steen et al (this false positives. An exciting recent development has issue) report an exciting and intriguing association been the independent replication of more modest posibetween susceptibility to TD in patients with schizotive results on chromosomes 6p and 22q. The lesson phrenia and homozygosity for the Ser9Gly variant gained from this experience to date seems to be that, as (allele 2) of the DRD3 gene. The published studies on always, independent replication is the gold standard. the relationship of schizophrenia to the D3 receptor Strongly positive linkage results should not be too gene are split about 50-50 between confirmations and readily accepted, neither should modest results be too non-replications. Steen and colleagues suggest that this readily rejected. This experience echoes that in studies discrepancy in the literature may be explained, at least of other complex disorders such as diabetes mellitus, partly, on the basis of inclusion or exclusion of patients where some early results were difficult to replicate with TD from the patient samples studied. While this until much larger datasets became available. The studis certainly a possibility several caveats need to be ies of D3DR in relationship to schizophrenia and TD should similarly be considered cautiously until more data become available.
of neuroleptic exposure and older age. On the other schizophrenia compared to that in patients with other diagnoses, who receive prolonged antipsychotic drug hand, patients who need higher neuroleptic doses and for longer periods of time may define a subgroup of treatment. This then raises a question: is the putative genetic predisposition to TD applicable to all the patients with schizophrenia. These patients may, for example, be more severely ill and/or less responsive to patients who receive neuroleptics or is this only a finding seen in patients with schizophrenia? neuroleptics and require greater amounts. Some investigators have reported an association between TD and negative symptoms of schizophrenia. 3 
Similarly,
The promise and peril of genetic association patients with TD have been frequently found to be cogstudies of TD nitively more impaired than those without TD. 4 Presence of a subtle movement disorder (such as
The study by Steen et al illustrates both the pluses and minuses of genetic association studies, especially for a parkinsonism) either prior to or early in response to neuroleptics has also been repeatedly shown to be a condition such as TD. This approach has great advantage in the study of genes with strong environmental risk factor for TD.
5 Indeed, some patients with schizophrenia have tremor, rigidity, and bradykinesia even interactions, and genes with relatively small effect. It is relatively straightforward to collect a sample of unrebefore receiving neuroleptics. 6, 7 Is it possible that these are the individuals with certain types of basal ganglia lated subjects with schizophrenia on neuroleptics for such a study. It would, however, be considerably more dysfunction who are susceptible to develop TD? In that case, it is conceivable that a specific genotype may be difficult to test this gene in a family sample, since the affected persons would be the subset of family memcharacterized by an increased likelihood or manifesting movement disorders including TD.
bers with schizophrenia who have TD. Such families with multiple cases of TD will inevitably be more rare Although TD is a side-effect of medications, constitutional predisposition is likely to play a role in its etithan those with schizophrenia alone. The major complicating factor in the identification ology. Indeed, TD occurs in some patients who have had relatively brief or low-dose treatment with neuroof genes for susceptibility to TD is that the primary etiological factor is environmental, namely exposure to leptics, while it may not develop in others despite long-term, high-dose drug therapy. 8 One type of constineuroleptics. Compared to this effect, genes may play a relatively small role in causation. It is therefore, crititutional predisposition could be genetic. Movement disorders such as Huntington's disease and dystonia cal to control for the effect of total neuroleptic amount, since there is a strong correlation between this and the musculorum deformans are well known examples of genetically transmitted extrapyramidal system disrisk of TD. The problems in obtaining accurate lifelong medication histories make this difficult in a retrospecorders. With drug-induced disorders, the contribution of hereditary factors is much more difficult to prove.
tive study, and this is clearly the direction for future studies of this finding. Even if patient samples were Previous attempts at demonstrating a genetic component to TD have produced mixed results. As Steen et well matched for such exposure, the noise introduced by the size of the neuroleptic effect may make difficult al cite, there have been a few reports of families with more than one member with TD. On the other hand, the detection of genetic effects. The advantage of the genetic association strategy in this case is its power to Jacob Brody of NIH who studied four pairs of monozygotic twin patients on long-term high-dose phenothiadetect genes of small effect where a candidate gene is being tested. In fact, this approach may be essential for zine treatment, found that the twins were discordant for the neurological side-effects of neuroleptics includa variety of complex disorders which result from the interaction of numerous small gene effects as has been ing TD. 8 Similarly, we had observed that only one member of a 50-year-old female quadruplet with recently discussed by Risch and Merikangas.
11
The potential artifacts affecting genetic association schizophrenia and a long history of neuroleptic treatment had definitive TD. 8 This does not rule out the studies have been well described, but most prominent are subtle sources of population stratification, ie, differpossibility of a genetic contribution to the development of TD, but suggests that, at best, it is likely to be ences in the case and control populations which affect allele frequencies, but are not directly related to the limited.
When discussing TD, two facts need to be borne in phenotype being studied. Differences in race and ethnicity are foremost, but other more subtle effects may mind. One is that dyskinesia can occur in the absence of neuroleptic treatment. There were reports of such play havoc in such studies. It is therefore, critical to carefully control for as many such factors as possible. spontaneous dyskinesia decades before antipsychotic drug treatment was introduced into psychiatry. While
Better yet are recently developed methods for intrafamilial association which include 'built-in' controls for numerous studies have shown that the incidence of dyskinesia increases several fold with long-term neurothis type of artifact. These samples are more difficult to obtain, but should be one of several next logical leptic treatment, it may be difficult to prove that, in a given patient, dyskinesia was directly induced by these steps given the findings of Steen et al. If the marker is indeed the predisposing mutation, then these sorts of drugs. The second fact to consider is that TD is not restricted to schizophrenia. We 9 and several other artifacts are less likely to be a problem. It has, however, not been demonstrated that the mutation affects recepgroups 10 have found that the risk of TD is not greater (and may sometimes be even lower) in patients with tor function, even though it does alter an amino acid.
It is possible that this mutation is simply in linkage University of California, San Diego; San Diego VA Medical Center disequilibrium with another mutation of functional significance.
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